ReviewInternational journal of molecular sciences2013
The clinical utilization of circulating cell free DNA (CCFDNA) in blood of cancer patients.
Review in International journal of molecular sciences, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 114 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
114 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Diagnostic Clinical Trials in Breast Cancer Brain Metastases: Barriers and Innovations.Clinical breast cancer · 2019Pooled it
- Tumor fraction in cell-free DNA as a biomarker in prostate cancer.JCI insight · 2018Trial
- MammaTrace - a tumor naïve cell-free DNA methylation test for minimal residual disease in breast cancer.NPJ precision oncology · 2026Article
- Liquid biopsy as a potential tool for diagnosis and clinical monitoring of cutaneous and uveal melanoma.The journal of liquid biopsy · 2025Review
- The Role of Ultrasonography in Predicting Genetic Characteristics of Endometrial Cancers.Journal of clinical medicine · 2025Article
- Detection of Genomic Copy Number Variations in Ovarian Cancer in the Peripheral Blood System.Cancers · 2025Article
- Cell-free DNA integrity and complement C4d as novel liquid biopsy biomarkers for paraneoplastic and non-paraneoplastic autoimmune encephalitis.Frontiers in immunology · 2025Article
- Article
- A comparative study on the detection of Mycobacterium leprae DNA in urine samples of leprosy patients using Rlep-PCR with other conventional samples.Molecular biology reports · 2024Article
- Targeted Sequencing of Human Satellite 2 Repeat Sequences in Plasma cfDNA Reveals Potential Breast Cancer Biomarkers.Diagnostics (Basel, Switzerland) · 2024Article
- Clinical evaluation of cell-free and cellular metagenomic next-generation sequencing of infected body fluids.Journal of advanced research · 2024Article
- Circulating Nucleic Acids in Colorectal Cancer: Diagnostic and Prognostic Value.Disease markers · 2024Review
- OvaPrint-A Cell-free DNA Methylation Liquid Biopsy for the Risk Assessment of High-grade Serous Ovarian Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
- Review
- False Positives in Brucellosis Serology: Wrong Bait and Wrong Pond?Tropical medicine and infectious disease · 2023Review
- Clinical Evidence of Circulating Tumor DNA Application in Aggressive Breast Cancer.Diagnostics (Basel, Switzerland) · 2023Review
- Hepatocellular carcinoma detection via targeted enzymatic methyl sequencing of plasma cell-free DNA.Clinical epigenetics · 2023Article
- Time-series prediction and detection of potential pathogens in bloodstream infection using mcfDNA sequencing.Frontiers in cellular and infection microbiology · 2023Article
- Clinical utility of liquid biopsy in canine oral malignant melanoma using cell-free DNA.Frontiers in veterinary science · 2023Article
- Monitoring plasma nucleosome concentrations to measure disease response and progression in dogs with hematopoietic malignancies.PloS one · 2023Article
54 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Qualitative and quantitative testing of circulating cell free DNA (CCFDNA) can be applied for the management of malignant and benign neoplasms. Detecting circulating DNA in cancer patients may help develop a DNA profile for early stage diagnosis in malignancies. The technical issues of obtaining, using, and analyzing CCFDNA from blood will be discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.